1. Division of Tuberculosis Elimination Centers for Disease Control and Prevention Tuberculosis in the United States National Tuberculosis Surveillance System Highlights from 2009

2. Reported TB Cases* United States, 1982–2009 Year No. of Cases *Updated as of July 1, 2010.

3. TB Morbidity United States, 2003–2009 Year No. Rate* *Cases per 100,000, updated as of July 1, 2010. 200314,8365.1 200414,4994.9 200514,0644.8 200613,7344.6 200713,2804.4 200812,9064.2 200911,5453.8

4. TB Case Rates,* United States, 2009 < 3.5 (year 2000 target) 3.6–3.8 > 3.8 (national average) D.C. *Cases per 100,000.

5. TB Case Rates* by Age Group United States, 1993–2009 Age Group (years) Cases per 100,000 *Updated as of July 1, 2010.

6. Reported TB Cases by Age Group, United States, 2009 25–44 yrs (34%) <15 yrs (6%) 15–24 yrs (11%) 45–64 yrs (30%) >65 yrs (20%)

7. TB Case Rates by Age Group and Sex, United States, 2009 Cases per 100,000

8. TB Case Rates by Race/Ethnicity* United States, 1993–2009** Cases per 100,000 WhiteBlack or African-American Hispanic American Indian/Alaska NativeAsian/Pacific Islander *All races are non-Hispanic. In 2003, Asian/Pacific Islander category includes persons who reported race as Asian only and/or Native Hawaiian or Other Pacific Islander only. **Updated as of July 1, 2010.

9. TB Case Rates by Age Group and Race/Ethnicity,* United States, 2009 Cases per 100,000 Age Group (yrs) *All races are non-Hispanic. Persons reporting two or more races accounted for less than 1% of all cases. American Indian/Alaska Native Asian Black or African-American Hispanic or Latino White Native Hawaiian/Other Pacific Islander

10. Reported TB Cases by Race/Ethnicity* United States, 2009 Hispanic or Latino (29%) Black or African-American (25%) Asian (28%) White (16%) American Indian or Alaska Native (1%) Native Hawaiian or Other Pacific Islander (1%) *All races are non-Hispanic. Persons reporting two or more races accounted for less than 1% of all cases.

11. Number of TB Cases in U.S.-born vs. Foreign-born Persons United States, 1993–2009* No. of Cases *Updated as of July 1, 2010.

12. Trends in TB Cases in Foreign-born Persons, United States, 1989–2009* No. of Cases Percentage *Updated as of July 1, 2010.

13. Reported TB Cases by Origin and Race/Ethnicity,* United States, 2009 *All races are non-Hispanic. Persons reporting two or more races accounted for less than 1% of all cases. **American Indian or Alaska Native and Native Hawaiian or Other Pacific Islander accounted for less than 1% of foreign-born cases and are not shown. U.S.-born Foreign-born** Native Hawaiian/ Other Pacific Islander (<1%) White (32%) Black or African American (42%) Hispanic or Latino (19%) Asian (3%) American Indian or Alaska Native (2%) Hispanic or Latino (36%) Asian (44%) White (5%) Black or African American (14%)

14. Percentage of TB Cases Among Foreign-born Persons, United States* >50% 25%–49% <25% 19992009 DC *Updated as of July 1, 2010.

15. TB Case Rates in U.S.-born vs. Foreign-born Persons United States, 1993–2009* Cases per 100,000 *Updated as of July 1, 2010.

16. TB Case Rates in U.S.-born vs. Foreign-born Persons United States,* 1993–2009** Cases per 100,000 *Includes the same data as slide 15, but rates presented on a logarithmic scale. **Updated as of July 1, 2010.

17. Countries of Birth of Foreign-born Persons Reported with TB United States, 2009 Mexico (23%) Philippines (12%) India (8%) Vietnam (8%) China (5%) Guatemala (3%) Haiti (3%) Other Countries (38%)

18. Percent of Foreign-born with TB by Time of Residence in U.S. Prior to Diagnosis, 2009 * Foreign-born TB patients for whom information on length of residence in the U.S. prior to diagnosis is unknown or missing.

19. Primary Anti-TB Drug Resistance United States, 1993–2009* % Resistant *Updated as of July 1, 2010. Note: Based on initial isolates from persons with no prior history of TB. Multidrug resistant TB (MDR TB) is defined as resistance to at least isoniazid and rifampin.

20. Primary MDR TB United States, 1993–2009* *Updated as of July 1, 2010. Note: Based on initial isolates from persons with no prior history of TB. MDR TB defined as resistance to at least isoniazid and rifampin. No. of Cases Percentage

21. Primary Isoniazid Resistance in U.S.-born vs. Foreign-born Persons United States, 1993–2009* % Resistant *Updated as of July 1, 2010. Note: Based on initial isolates from persons with no prior history of TB.

22. Primary MDR TB in U.S.-born vs. Foreign-born Persons, United States, 1993–2009* % Resistant *Updated as of July 1, 2010. Note: Based on initial isolates from persons with no prior history of TB. MDR TB defined as resistance to at least isoniazid and rifampin.

23. XDR TB Case Count defined on Initial DST † by Year, 1993–2009* Case Count Year of Diagnosis † Drug susceptibility test. *Reported incident cases as of July 1, 2010. Extensively drug-resistant TB (XDR TB) is defined as resistance to isoniazid and rifampin, plus resistance to any fluoroquinolone and at least one of three injectable second-line anti-TB drugs.

24. % with Test Results *Updated as of July 1, 2010. Note: Includes TB patients with positive, negative, or indeterminate HIV test results. Persons from California reported with AIDS only through 2004. (HIV test results are not reported from California) Reporting of HIV Test Results in Persons with TB by Age Group United States, 1993–2009*

25. Estimated HIV Coinfection in Persons Reported with TB, United States, 1993–2009* % Coinfection *Updated as of July 1, 2010. Note: Minimum estimates based on reported HIV-positive status among all TB cases in the age group.

26. Mode of Treatment Administration in Persons Reported with TB United States, 1993–2007* *Updated as of July 1, 2010. **Percentage of total cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed, and excluding cases with missing or unknown mode of treatment administration. Directly observed therapy (DOT); Self-administered therapy (SA) **

27. Completion of TB Therapy United States, 1993–2007* *Updated as of July 1, 2010. **Healthy People 2010 target: 90% completed in 1 yr or less. Note: Excludes persons with initial isolate rifampin resistant, or patient with meningeal disease, or pediatric patient (aged <15) with miliary disease or positive blood culture. Percentage **